]>
IRCT138810193029N1 IRCT 2010-03-01 Tehran University of Medical Sciences and Health services Duloxetine in ADHD Duloxetine vs Methylphenidate in adolescents with ADHD: A randomized trial 2009-12-01 anticipated 30 Complete https://irct.ir/trial/3013 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 ADHD. Intervention 1: Duloxetine, 30-60 mg/day, starting dose 30 mg/day for 1 week and 60 mg/day for the following 5 weeks. Intervention 2: Methylphenidate, starting dose: 10 mg/ day divided in two doses for 1 week and 20, 30 and 40 mg/day divided in 3 doses in weeks 2, 3 and 4 respectively according to the patient tolerance and continue in weeks 5 and 6.
public Dr. Javad Mahmoudi-Gharaei
Psychiatry and Psychology research Center, Roozbeh Hospital, South Kargar Ave.,
Tehran Iran (Islamic Republic of) +98 912 226 2590 jmahmoudi@razi.tums.ac.ir Tehran University of Medical Sciences scientific Dr Javad Mahmoudi-Gharaei
Roozbeh hospital, Psychiatry and psychology research center, South kargar Ave.
Tehran Iran (Islamic Republic of) +98 912 226 2590 jmahmoudi@razi.tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria: Diagnosis of ADHD according to DSM-IV-TR Criteria, age range of 11 to 18 years Exclusion criteria: Presence of mental retardation, cardiac problems, known contraindications to study drugs, Comorbidity of severe major depression, conduct disorder, bipolar or psychotic disorders, epilepsy taking anticonvulsants at the time of enrollment and during the trial, pregnancy or lactation, refusal to participate 11 years 18 years Both F90.0 Disturbance of activity and attention Treatment - Drugs Treatment - Drugs Duloxetine, 30-60 mg/day, starting dose 30 mg/day for 1 week and 60 mg/day for the following 5 weeks Methylphenidate, starting dose: 10 mg/ day divided in two doses for 1 week and 20, 30 and 40 mg/day divided in 3 doses in weeks 2, 3 and 4 respectively according to the patient tolerance and continue in weeks 5 and 6 ADHD severity of symptoms. Timepoint: Baseline, Every 2 weeks, End point. Method of measurement: Conner's and ADHD rating Scale. Drug side effects. Timepoint: every 2 weeks and end point. Method of measurement: Questionnaire. Tehran University of Medical Sciences and Health services Approved 2009-12-01 Tehran University of Medical Sciences and Health Services Qods Ave, Keshavarz Blvd. Tehran Iran (Islamic Republic of)